title: Letter by Greyson regarding article, "High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury".
authors.forename: Clifford R
authors.initials: CR
authors.lastname: Greyson
mesh_terms: D000244:Adenosine Diphosphate / Q000378:metabolism*; D000255:Adenosine Triphosphate / Q000378:metabolism*; D000818:Animals; D002316:Cardiotonic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D054059:Coronary Occlusion / Q000188:drug therapy* / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D005492:Folic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D020138:Hyperhomocysteinemia / Q000188:drug therapy; D009203:Myocardial Infarction / Q000209:etiology / Q000473:pathology; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D009569:Nitric Oxide / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D052250:Nitric Oxide Synthase Type III; D018384:Oxidative Stress / Q000187:drug effects; D011292:Premedication; D011355:Prodrugs / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011687:Purines / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar
chemical_list: D002316:Cardiotonic Agents; D011355:Prodrugs; D011687:Purines; D009569:Nitric Oxide; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D005492:Folic Acid; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; C496316:Nos3 protein, rat